Warfarin

David Green; Gordon Caldwell; Anthony D. Toft; Paul A. Lotke; David G. Pfister; Malcolm L. Ecker; Philip W. Yule; Stanford Wessler; Sanford N. Gitel

doi:10.1056/NEJM198412133112418

Warfarin

David Green, Gordon Caldwell, Anthony D. Toft, Paul A. Lotke, David G. Pfister, Malcolm L. Ecker, Philip W. Yule, Stanford Wessler, Sanford N. Gitel

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Abstract

To the Editor: With regard to the excellent review of warfarin by Wessler and Gitel (Sept. 6 issue),¹ the importance of protein C in preventing thrombosis in patients treated with warfarin has recently been emphasized by two reports of the development of skin and soft-tissue necrosis in warfarin-treated patients with a hereditary protein C deficiency.²^,³ A review of 17 previously reported cases of warfarin necrosis revealed that in all but 2 the onset of thrombosis coincided with prothrombin times that exceeded the therapeutic range, and it occurred within the first five days of treatment, suggesting extreme sensitivity to the hypoprothrombinemic.

Original language	English (US)
Pages (from-to)	1578-1580
Number of pages	3
Journal	New England Journal of Medicine
Volume	311
Issue number	24
DOIs	https://doi.org/10.1056/NEJM198412133112418
State	Published - Dec 13 1984

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM198412133112418

Cite this

@article{70fe62fcc40f445795a6b04fbc330ea0,

title = "Warfarin",

abstract = "To the Editor: With regard to the excellent review of warfarin by Wessler and Gitel (Sept. 6 issue),1 the importance of protein C in preventing thrombosis in patients treated with warfarin has recently been emphasized by two reports of the development of skin and soft-tissue necrosis in warfarin-treated patients with a hereditary protein C deficiency.2,3 A review of 17 previously reported cases of warfarin necrosis revealed that in all but 2 the onset of thrombosis coincided with prothrombin times that exceeded the therapeutic range, and it occurred within the first five days of treatment, suggesting extreme sensitivity to the hypoprothrombinemic.",

author = "David Green and Gordon Caldwell and Toft, {Anthony D.} and Lotke, {Paul A.} and Pfister, {David G.} and Ecker, {Malcolm L.} and Yule, {Philip W.} and Stanford Wessler and Gitel, {Sanford N.}",

year = "1984",

month = dec,

day = "13",

doi = "10.1056/NEJM198412133112418",

language = "English (US)",

volume = "311",

pages = "1578--1580",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "24",

}

TY - JOUR

T1 - Warfarin

AU - Green, David

AU - Caldwell, Gordon

AU - Toft, Anthony D.

AU - Lotke, Paul A.

AU - Pfister, David G.

AU - Ecker, Malcolm L.

AU - Yule, Philip W.

AU - Wessler, Stanford

AU - Gitel, Sanford N.

PY - 1984/12/13

Y1 - 1984/12/13

N2 - To the Editor: With regard to the excellent review of warfarin by Wessler and Gitel (Sept. 6 issue),1 the importance of protein C in preventing thrombosis in patients treated with warfarin has recently been emphasized by two reports of the development of skin and soft-tissue necrosis in warfarin-treated patients with a hereditary protein C deficiency.2,3 A review of 17 previously reported cases of warfarin necrosis revealed that in all but 2 the onset of thrombosis coincided with prothrombin times that exceeded the therapeutic range, and it occurred within the first five days of treatment, suggesting extreme sensitivity to the hypoprothrombinemic.

AB - To the Editor: With regard to the excellent review of warfarin by Wessler and Gitel (Sept. 6 issue),1 the importance of protein C in preventing thrombosis in patients treated with warfarin has recently been emphasized by two reports of the development of skin and soft-tissue necrosis in warfarin-treated patients with a hereditary protein C deficiency.2,3 A review of 17 previously reported cases of warfarin necrosis revealed that in all but 2 the onset of thrombosis coincided with prothrombin times that exceeded the therapeutic range, and it occurred within the first five days of treatment, suggesting extreme sensitivity to the hypoprothrombinemic.

UR - http://www.scopus.com/inward/record.url?scp=0021688699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021688699&partnerID=8YFLogxK

U2 - 10.1056/NEJM198412133112418

DO - 10.1056/NEJM198412133112418

M3 - Letter

C2 - 6504088

AN - SCOPUS:0021688699

SN - 0028-4793

VL - 311

SP - 1578

EP - 1580

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -

Warfarin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this